Top in ID: Paxlovid unlikely contributes to COVID-19 rebound; a roundup of 2023 guidelines
Click Here to Manage Email Alerts
Two separate analyses of studies and trials suggest that COVID-19 rebound is not linked to Paxlovid or other antiviral drugs.
The findings contradict other studies that indicated a higher frequency of COVID-19 rebound among people treated with Paxlovid (nirmatrelvir/ritonavir, Pfizer).
“Rebound is typically described as a recurrence of symptoms after recovery or a new positive viral test after testing negative,” Pragna Patel, MD, MPH, DRM&H, chief medical officer in the Coronavirus and Other Respiratory Viruses division of the CDC’s National Center for Immunization and Respiratory Diseases, told Healio. “We found that there was no consistent association between treatment for COVID-19 and COVID-19 rebound. Also, we found that COVID-19 rebound can happen among patients whether they received antiviral treatments or not.”
It was the top story in infectious disease last week.
Another top story was a collection of articles about ID-related guidelines released in 2023, including recommendations on sexually transmitted disease prevention, diabetic foot infections and more.
Read these and more top stories in infectious disease below:
Paxlovid unlikely to contribute to COVID-19 rebound
SARS-CoV-2 rebound risk is more likely related to the individual person, rather than reinfection or resistance to treatment such as Paxlovid, according to two studies. Read more.
Doxy-PEP, diabetic foot infections and more: The year in ID guidelines
New guidance was published in 2023 for STD prevention, diabetic foot infections, infective endocarditis and more. Read more.
COVAX to end as COVID-19 vaccines move to routine immunization programs
COVAX, the multinational program launched in 2020 to deliver COVID-19 vaccines to low- and lower-middle income countries, will end on Dec. 31, 2023, as the vaccines shift to routine immunization programs. Read more.
Pneumonia, candidiasis and more: The non-vaccine approvals of 2023
The FDA in 2023 approved treatments for several hospital-associated infections and fully approved a long-used COVID-19 medication, among other non-vaccine-related regulatory decisions. Read more.
Developments in hepatitis care: New CDC recommendations and more
As viral hepatitis continues to be a major health concern in the infectious disease field, recent research has highlighted the importance of testing and treatment. Read more.